Literature DB >> 22961072

[Diabetic nephropathy].

A Sämann1, G Wolf.   

Abstract

Diabetic nephropathy can impact on quality of life, morbidity and mortality of affected patients. The prognosis can be improved by early diagnosis and therapy. The association between renal insufficiency, cardiovascular morbidity and mortality is of importance. Annual nephropathy screening should involve the analyses of albuminuria and glomerular filtration rate (GFR). After having detected albuminuria or reduced GFR, renal ultrasound imaging and microscopic examination of the urine sediment is necessary. Patients with abnormal or ambiguous findings should be referred to a nephrologist and may require a renal biopsy. Patients with renal complications can benefit from a goal-orientated intervention involving an antidiabetic, antihypertensive and lipid-modifying therapy. The avoidance of potentially nephrotoxic prescriptions and a renal function dependent dose-adjustment of medications are of importance in patients with declining renal function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961072     DOI: 10.1007/s00108-012-3129-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  39 in total

1.  Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

Authors:  Ravi Retnakaran; Carole A Cull; Kerensa I Thorne; Amanda I Adler; Rury R Holman
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

2.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

Review 3.  Renin-angiotensin-aldosterone system and progression of renal disease.

Authors:  Christiane Rüster; Gunter Wolf
Journal:  J Am Soc Nephrol       Date:  2006-10-11       Impact factor: 10.121

4.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

5.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

6.  Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.

Authors:  K Rave; T Heise; A Pfützner; L Heinemann; P T Sawicki
Journal:  Diabetes Care       Date:  2001-05       Impact factor: 19.112

7.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors:  Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

Review 8.  How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease?

Authors:  Tobias Pinkau; Karl F Hilgers; Roland Veelken; Johannes F E Mann
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

9.  Predicting diabetic nephropathy in insulin-dependent patients.

Authors:  C E Mogensen; C K Christensen
Journal:  N Engl J Med       Date:  1984-07-12       Impact factor: 91.245

10.  Nonalbuminuric renal insufficiency in type 2 diabetes.

Authors:  Richard J MacIsaac; Con Tsalamandris; Sianna Panagiotopoulos; Trudy J Smith; Karen J McNeil; George Jerums
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

View more
  2 in total

1.  Diagnostic value of the combined measurement of serum hcy, serum cys C, and urinary microalbumin in type 2 diabetes mellitus with early complicating diabetic nephropathy.

Authors:  Tengkai Wang; Qian Wang; Zhimei Wang; Zuomin Xiao; Lunqin Liu
Journal:  ISRN Endocrinol       Date:  2013-09-18

2.  Diagnostic value of cystatin C for diagnosis of early renal damages in type 2 diabetic mellitus patients: The first experience in Iran.

Authors:  Mitra Javanmardi; Namam-Ali Azadi; Sabrieh Amini; Mohammad Abdi
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.